biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Bioasis gives hope for challenging neurological treatments

<< Previous

Bullboard Posts

Next >>

Comment by AlfredSisleyon Apr 07, 2021 12:03pm

162 Views

Post# 32949548

RE:Bioasis gives hope for challenging neurological treatments

With promising results already showing, and new results coming soon, it's not hard to see that Bioasis will be instrumental in what could be the next big breakthrough in neurological treatment.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China